SignatureFD’s Jasper Therapeutics JSPR Stock Holding History

SignatureFD’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	-$207	–	3359
2024 Q3	$207	Buy	+11	New	+$219	﹤0.01%	3162

Other funds holding JSPR

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SignatureFD's JSPR Position: Q4 2024 in Review

SignatureFD sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 11 shares — an estimated $207 sold.

SignatureFD first reported a position in JSPR in Q3 2024 and held it in 1 quarter. The position peaked at $207 in Q3 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

SignatureFD reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
SignatureFD sold 11 Jasper Therapeutics shares in Q4 2024, an estimated $207.
SignatureFD first reported a position in Jasper Therapeutics in Q3 2024 and held it in 1 quarter.
SignatureFD's Jasper Therapeutics position peaked at $207 in Q3 2024.
87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on SignatureFD's 13F filing for Q4 2024, filed 10 Feb 2025.